Explore the multiple dimensions of ITP2,3,6
ITP is characterized by low platelet counts and symptoms like bleeding and bruising2
Platelet counts <100,000/μL can indicate ITP
Platelet counts <50,000/μL can indicate severe thrombocytopenia5,7,8
In ITP, increased platelet clearance and decreased platelet production result in bleeding symptoms in around 60% of patients. Bleeding symptoms vary and can include5,9:
Petechiae and purpura, usually on the extremities2,10
Bleeding blisters and epistaxis2,10
Heavy menstrual bleeding2
Intracranial hemorrhage9
Severe bleeding occurs in 7% to 10% of adult patients and typically correlates with lower platelet counts.11,12*
*As seen in a cross-sectional study of 302 French patients, as well as in a systematic review of 147 clinical studies of adults and children with primary ITP.11,12
Next: ITP is about more than platelets
Learn how ITP can have a major impact on patients' quality of life.2
1. Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199-207. 2. Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188-198. 3. Kuter DJ, Gouia I, Cordoba M, et al. Clinical burden of illness in patients with persistent or chronic primary immune thrombocytopenia treated with advanced therapies in the United States. Poster presented at: American Society of Hematology Annual Meeting & Exposition; December 7-10, 2024; San Diego, CA. 4. Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton's tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;9:668131. 5. Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381(10):945-955. 6. Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98(1):24-33. 7. Rovó A, Cantoni N, Samii K, et al. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: results from a questionnaire conducted in Switzerland, Austria, and Belgium. PLoS One. 2022;17(4):e0267342. 8. Williamson DR, Albert M, Heels-Ansdell D, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207-1215. 9. Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia. J Clin Med. 2021;10(5):1004. 10. Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495-520. 11. Piel-Julian ML, Mahévas M, Germain J, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018;16(9):1830-1842. 12. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457-464.